-
Mashup Score: 0Dr Bhave on the Impact of New Treatment Strategies on the Landscape of HR+/HER2– Breast Cancer - 10 month(s) ago
Manali Bhave, MD, discusses the impact of new treatment strategies on the landscape of hormone receptor–positive/HER2-negative breast cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Dr Rini on the OPTIC RCC Trial in Advanced Kidney Cancer - 10 month(s) ago
Brian I. Rini, MD, FASCO, discusses efforts to utilize genetic testing to improve treatment selection in renal cell carcinoma through the phase 2 OPTIC RCC trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Brian I. Rini, MD, FASCO, @VUMC_Cancer, discusses efforts to utilize genetic testing to improve treatment selection in renal cell carcinoma through the phase 2 OPTIC RCC trial. #kcsm https://t.co/DPeHPf718T
-
-
Mashup Score: 0Dr Han on the Use of HIPEC in Ovarian Cancer - 10 month(s) ago
Ernest S. Han, MD, PhD, discusses the use of hyperthermic intraperitoneal chemotherapy in ovarian cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ernest S. Han, MD, PhD, of @cityofhope, discusses the use of hyperthermic intraperitoneal chemotherapy in ovarian cancer. #ovca https://t.co/OXFAJQ466m https://t.co/7BDOSD7kJa
-
-
Mashup Score: 0
Stephen V. Liu, MD, highlighted the importance of next-generation sequencing in lung cancer, key trials that have shifted the non–small cell lung cancer treatment landscape, and detailed ongoing research at Georgetown University Lombardi Comprehensive Cancer Center.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Stephen V. Liu, MD, of @LombardiCancer, highlights the importance of next-generation sequencing in lung cancer, key trials that have shifted the NSCLC treatment landscape, and detailed ongoing research at his institution. #lcsm https://t.co/CXOGBKfG6m
-
-
Mashup Score: 0Dr Noonan on Practice-Changing Trials in HCC - 10 month(s) ago
Anne M. Noonan, MBBCh, discusses recent practice-changing trials for the treatment of patients with hepatocellular carcinoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Anne M. Noonan, MBBCh, @OSUCCC_James, discusses recent practice-changing trials for the treatment of patients with hepatocellular carcinoma. #hcc #oncology https://t.co/MSEJhHIVaF https://t.co/cwhN3IMr2x
-
-
Mashup Score: 0
John L. Hays, MD, PhD, discusses the evolution of the treatment paradigm for patients with metastatic colorectal cancer who experience disease progression following standard chemotherapy regimens.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
John L. Hays, MD, PhD, @OSUCCC_James, discusses the evolution of the treatment paradigm for patients with metastatic colorectal cancer who experience disease progression following standard chemotherapy regimens. #crcsm https://t.co/R4Pnj85ato
-
-
Mashup Score: 0Practice-Changing Trials Expand Armamentarium and Improve Guidance in Advanced Breast Cancers - 10 month(s) ago
Several landmark trials have led to FDA approval milestones across all breast cancer subtypes in the past 5 years, each continuing to change the navigation of treatment approaches in clinical practice.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Several landmark trials have led to FDA approval milestones across all breast cancer subtypes in the past 5 years, each continuing to change the navigation of treatment approaches in clinical practice. @SitemanCenter #bcsm https://t.co/AjaLU4TZl8 https://t.co/qaQru2nMM9
-
-
Mashup Score: 0
Marilyn Huang, MD, contextualizes findings within the endometrial cancer treatment landscape and emphasizes the unanswered questions regarding optimal therapies for patients with mismatch repair–proficient disease.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Marilyn Huang, MD, @SylvesterCancer, contextualizes findings within the endometrial cancer treatment landscape and emphasizes the unanswered questions regarding optimal therapies for patients with mismatch repair–proficient disease. #gynsm https://t.co/RLyGuqyqoI https://t.co/B9V5Ib7ado
-
-
Mashup Score: 0
Edgardo S. Santos, MD, FACP, discusses the impact of treatment with cemiplimab plus chemotherapy in patients with squamous non–small cell lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Edgardo S. Santos, MD, FACP, @FAUMedSchool, discusses the impact of treatment with cemiplimab plus chemotherapy in patients with squamous non–small cell lung cancer. #lcsm https://t.co/X1usYO3awt
-
-
Mashup Score: 0Dr Ademuyiwa on the Sequencing of First-line CDK4/6 Inhibitors in HR+/HER2– Breast Cancer - 10 month(s) ago
Foluso Bisi Ademuyiwa, MD, MPH, MSCI, discusses the optimal sequencing of current CDK4/6 inhibitors in the first-line setting for hormone receptor (HR)–positive, HER2-negative breast cancer based on updated efficacy and safety data.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Foluso Bisi Ademuyiwa, MD, MPH, MSCI, of @SitemanCenter, discusses the optimal sequencing of current CDK4/6 inhibitors in the first-line setting for hormone receptor–positive, HER2-negative breast cancer based on updated efficacy and safety data. #bcsm https://t.co/0WIzIyn0E8 https://t.co/c8d5DMQ9v9
-
Manali Bhave, MD, of @WinshipAtEmory, discusses the impact of new treatment strategies on the landscape of hormone receptor–positive/HER2-negative breast cancer. #bcsm https://t.co/Ki0I0E1b9I https://t.co/esxs2nwlKe